Mingqing Zhu

Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

Xiaowen Tang, Lin Yang, Zheng Li et al. · PubMed · 2018 · 412 citations · Full text

Medicine, Hematology, Immunology +17

Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma

Hongyu Bao, Miao Jiang, Mingqing Zhu et al. · International Journal of Hematology · 2009 · 92 citations

Medicine, Cell Biology, Oncology +10

Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myeloma

Xiaolan Shi, Lingzhi Yan, Jingjing Shang et al. · American Journal of Hematology · 2022 · 79 citations · Full text

Medicine, Hematology, Oncology +17

Akt-mediated platelet apoptosis and its therapeutic implications in immune thrombocytopenia

Mengxing Chen, Rong Yan, Kangxi Zhou et al. · Proceedings of the National Academy of Sciences · 2018 · 74 citations · Full text

Life Sciences, Hematology, Immunology +17

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma

Lingzhi Yan, Su Qu, Jingjing Shang et al. · Cancer Medicine · 2020 · 51 citations · Full text

Medicine, Hematology, Immunology +17